Coronavirus 2019-2020 thread (no unsubstantiated rumours!)


Registered Member
I suppose that means producing bigger quantities faster?
Not necessarily.

Synthesis of mRNA is actually not as high throughput as proteins/viruses. It's linear throughput instead of exponential.

It is easier during the development stage.


Senior Member
You know what @AndrewS , I think I'm going to say I don't know.

There's also chance for the mRNA to break up and produce fragmented proteins and potentially unwanted antibodies.

They don't have enough infected patients to make conclusions about the safety of the translated proteins o_O
Please, Log in or Register to view URLs content!

In the US, the "2005 Public Readiness and Emergency Preparedness Act (PREP)" more broadly excludes tort claims from products that help to control a public health crisis. This act has been triggered in relation to COVID-19 in the US by the Secretary of HHS declaring a public health emergency, effective from February 4th, 2020. These provisions mean that qualified pandemic products are "immune from liability under federal and state law with respect to all claims for loss caused by, arising out of, relating to, or resulting from the administration to or use by an individual of a covered countermeasure if a Declaration has been issued with respect to such countermeasure."


Registered Member
Hi Gatekeeper,

WOW!!! :D China is showing leadership and is very confident of its ability and its vaccine. Xi is casting off Deng mantra of hide your strength, He is really giving Trump the middle finger, go Xi , show him who's the Daddy....LoL:cool:
Well, he's not known as Xi dada for nothing. Lol


Senior Member
I am suspected the usefulness of remdesivir. It is not just WHO but China CDC also finds remdesvir is not effective against covid-19. FDA might have allowed political and business interests to influence its decision. Just remember how FAA used to be the gold standard before 737 Max. I think US regulators have been getting too cozy with the Wall st and big businesses that they failed to regulate and protect public interests.

WHO tells doctors not to use Gilead’s remdesivir as a coronavirus treatment, splitting with FDA

Please, Log in or Register to view URLs content!

A World Health Organization panel advised doctors Thursday against using
Please, Log in or Register to view URLs content!
’ antiviral drug remdesivir as a treatment for patients hospitalized with
Please, Log in or Register to view URLs content!
, saying there is currently “no evidence” that it improves survival or shortens recovery time — standing in stark contrast to U.S. regulatory guidance on the drug.

The WHO Guideline Development Group, a panel of international experts who provide advice to the agency, said its recommendation is based on new data comparing the effects of several drug treatments, including data from four international randomized trials involving more than 7,000 patients hospitalized with the disease.

“After thoroughly reviewing this evidence, the WHO GDG expert panel, which includes experts from around the world including four patients who have had covid-19, concluded that remdesivir has no meaningful effect on mortality or on other important outcomes for patients, such as the need for mechanical ventilation or time to clinical improvement,” the group wrote in a press release.
The recommendation was published in the British medical trade journal The BMJ on Friday in the U.K.

In an emailed statement, Gilead said remdesivir “is recognized as a standard of care for the treatment of hospitalized patients with COVID-19 in guidelines from numerous credible national organizations, including the US National Institutes of Health and Infectious Diseases Society of America, Japan, UK and Germany.”

“We are disappointed the WHO guidelines appear to ignore this evidence at a time when cases are dramatically increasing around the world and doctors are relying on Veklury as the first and only approved antiviral treatment for patients with COVID-19 in approximately 50 countries,” Gilead spokesman Chris Ridley said in a statement.

Remdesivir, under the brand name Veklury, is administered in a hospital setting via an IV. Gilead has said the medication should only be administered in a hospital or in a health-care setting that can provide acute care comparable with inpatient hospital care.
The majority of patients treated with remdesivir receive a five-day course using six vials of the drug. The company is also developing an inhaled version of the medication, which it will administer through a nebulizer, a delivery device that can turn liquid medicines into mist.

The drug received worldwide attention as a potentially effective treatment for the coronavirus earlier in the year after a study funded by the National Institutes of Health found that it modestly reduced the recovery time in some patients who were hospitalized with Covid-19. It was one of the drugs used to treat President Donald Trump, who tested positive for the virus last month.

Please, Log in or Register to view URLs content!
, the Food and Drug Administration formally approved the drug for adults and pediatric patients 12 years of age and older who require hospitalization for Covid-19. It is now the first and only drug approved in the U.S. to treat the coronavirus, which has infected roughly 56.4 million people worldwide and killed about1.4 million.
Dr. Anthony Fauci, the nation’s leading infectious disease expert, has praised the drug, saying it
Please, Log in or Register to view URLs content!

Some medical experts note data on the drug’s effectiveness has been mixed. In October, a study coordinated by the WHO indicated that the medication had
Please, Log in or Register to view URLs content!
on death rates among hospitalized patients. The study was conducted in 405 hospitals across 30 countries on 11,266 patients, with 2,750 given remdesivir.

Gilead has publicly questioned the findings of the WHO study,
Please, Log in or Register to view URLs content!
in October that other trials show the treatment cut recovery time. “The emerging (WHO) data appears inconsistent, with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of remdesivir,” Gilead told Reuters.

The WHO panel acknowledged that evidence so far does not prove that remdesivir “has no benefit.”
But it added given the possibility of harm as well as the high cost and resources need to administer the drug, it is an “appropriate recommendation.” The group said it supports continued enrollment in trials evaluating the drug.